150 related articles for article (PubMed ID: 8405081)
1. Evaluation of truncated neuropeptide Y analogues with modifications of the tyrosine residue in position 1 on Y1, Y2 and Y3 receptor sub-types.
Dumont Y; Satoh H; Cadieux A; Taoudi-Benchekroun M; Pheng LH; St-Pierre S; Fournier A; Quirion R
Eur J Pharmacol; 1993 Jul; 238(1):37-45. PubMed ID: 8405081
[TBL] [Abstract][Full Text] [Related]
2. Peptide YY derivatives as selective neuropeptide Y/peptide YY Y1 and Y2 agonists devoided of activity for the Y3 receptor sub-type.
Dumont Y; Cadieux A; Pheng LH; Fournier A; St-Pierre S; Quirion R
Brain Res Mol Brain Res; 1994 Oct; 26(1-2):320-4. PubMed ID: 7854062
[TBL] [Abstract][Full Text] [Related]
3. Conformational and biological studies of neuropeptide Y analogs containing structural alterations.
Fournier A; Gagnon D; Quirion R; Cadieux A; Dumont Y; Pheng LH; St-Pierre S
Mol Pharmacol; 1994 Jan; 45(1):93-101. PubMed ID: 8302286
[TBL] [Abstract][Full Text] [Related]
4. Ligand binding and functional effects of systematic double D-amino acid residue substituted neuropeptide Y analogs on Y1 and Y2 receptor types.
Grundemar L; Kahl U; Callréus T; Langel U; Bienert M; Beyermann M
Regul Pept; 1996 Apr; 62(2-3):131-6. PubMed ID: 8795076
[TBL] [Abstract][Full Text] [Related]
5. Activation of neuropeptide Y1 and neuropeptide Y2 receptors by substituted and truncated neuropeptide Y analogs: identification of signal epitopes.
Grundemar L; Krstenansky JL; Håkanson R
Eur J Pharmacol; 1993 Mar; 232(2-3):271-8. PubMed ID: 8467862
[TBL] [Abstract][Full Text] [Related]
6. Apparent affinity and potency of BIBP3226, a non-peptide neuropeptide Y receptor antagonist, on purported neuropeptide Y Y1, Y2 and Y3 receptors.
Jacques D; Cadieux A; Dumont Y; Quirion R
Eur J Pharmacol; 1995 May; 278(1):R3-5. PubMed ID: 7664808
[TBL] [Abstract][Full Text] [Related]
7. Functional effects and ligand binding of chimeric galanin-neuropeptide Y (NPY) peptides on NPY and galanin receptor types.
Kahl U; Langel U; Bartfai T; Grundemar L
Br J Pharmacol; 1994 Apr; 111(4):1129-34. PubMed ID: 7518295
[TBL] [Abstract][Full Text] [Related]
8. Comparative structural requirements of brain neuropeptide Y binding sites and vas deferens neuropeptide Y receptors.
Martel JC; Fournier A; St-Pierre S; Dumont Y; Forest M; Quirion R
Mol Pharmacol; 1990 Oct; 38(4):494-502. PubMed ID: 2172766
[TBL] [Abstract][Full Text] [Related]
9. BODIPY-conjugated neuropeptide Y ligands: new fluorescent tools to tag Y1, Y2, Y4 and Y5 receptor subtypes.
Dumont Y; Gaudreau P; Mazzuferi M; Langlois D; Chabot JG; Fournier A; Simonato M; Quirion R
Br J Pharmacol; 2005 Dec; 146(8):1069-81. PubMed ID: 16231000
[TBL] [Abstract][Full Text] [Related]
10. Potent and selective tools to investigate neuropeptide Y receptors in the central and peripheral nervous systems: BIB03304 (Y1) and CGP71683A (Y5).
Dumont Y; Cadieux A; Doods H; Fournier A; Quirion R
Can J Physiol Pharmacol; 2000 Feb; 78(2):116-25. PubMed ID: 10737674
[TBL] [Abstract][Full Text] [Related]
11. Structure-function studies on neuropeptide Y and pancreatic polypeptide--evidence for two PP-fold receptors in vas deferens.
Jørgensen JC; Fuhlendorff J; Schwartz TW
Eur J Pharmacol; 1990 Sep; 186(1):105-14. PubMed ID: 2178092
[TBL] [Abstract][Full Text] [Related]
12. Y1 and Y2 receptor selective neuropeptide Y analogues: evidence for a Y1 receptor subclass.
Kirby DA; Koerber SC; May JM; Hagaman C; Cullen MJ; Pelleymounter MA; Rivier JE
J Med Chem; 1995 Oct; 38(22):4579-86. PubMed ID: 7473586
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226.
Doods HN; Wienen W; Entzeroth M; Rudolf K; Eberlein W; Engel W; Wieland HA
J Pharmacol Exp Ther; 1995 Oct; 275(1):136-42. PubMed ID: 7562541
[TBL] [Abstract][Full Text] [Related]
14. Discrimination by benextramine between the NPY-Y1 receptor subtypes present in rabbit isolated vas deferens and saphenous vein.
Palea S; Corsi M; Rimland JM; Trist DG
Br J Pharmacol; 1995 May; 115(1):3-10. PubMed ID: 7647980
[TBL] [Abstract][Full Text] [Related]
15. Neuropeptide Y: Y1 and Y2 affinities of the complete series of analogues with single D-residue substitutions.
Kirby DA; Boublik JH; Rivier JE
J Med Chem; 1993 Nov; 36(24):3802-8. PubMed ID: 8254609
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationships with neuropeptide Y analogues: a comparison of human Y1-, Y2- and rat Y2-like systems.
Cox HM; Tough IR; Ingenhoven N; Beck-Sickinger AG
Regul Pept; 1998 Sep; 75-76():3-8. PubMed ID: 9802388
[TBL] [Abstract][Full Text] [Related]
17. Characterization of Y3 receptor-mediated synaptic inhibition by chimeric neuropeptide Y-peptide YY peptides in the rat brainstem.
Glaum SR; Miller RJ; Rhim H; Maclean D; Georgic LM; MacKenzie RG; Grundemar L
Br J Pharmacol; 1997 Feb; 120(3):481-7. PubMed ID: 9031753
[TBL] [Abstract][Full Text] [Related]
18. Characterization of neuropeptide Y binding sites in rat brain membrane preparations using [125I][Leu31,Pro34]peptide YY and [125I]peptide YY3-36 as selective Y1 and Y2 radioligands.
Dumont Y; Fournier A; St-Pierre S; Quirion R
J Pharmacol Exp Ther; 1995 Feb; 272(2):673-80. PubMed ID: 7853181
[TBL] [Abstract][Full Text] [Related]
19. Failure of the putative neuropeptide Y antagonists, benextramine and PYX-2, to inhibit Y2 receptors in rat isolated prostatic vas deferens.
Palea S; Corsi M; Rimland JM; Trist DG; Ratti E
Br J Pharmacol; 1995 Nov; 116(5):2401-6. PubMed ID: 8581275
[TBL] [Abstract][Full Text] [Related]
20. Truncated, branched, and/or cyclic analogues of neuropeptide Y: importance of the pancreatic peptide fold in the design of specific Y2 receptor ligands.
Reymond MT; Delmas L; Koerber SC; Brown MR; Rivier JE
J Med Chem; 1992 Oct; 35(20):3653-9. PubMed ID: 1433176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
